摘要
目的探讨文拉法辛缓释剂联合森田疗法治疗肠易激综合征的临床疗效及安全性。方法对50例肠易激综合征患者应用文拉法辛缓释剂联合森田疗法进行观察治疗,2mo为1疗程,共6mo,采用抑郁自评量表及焦虑自评量表评定临床疗效并与全国常模比较。结果肠易激综合征患者治疗前与常模比较有显著的焦虑、抑郁情绪(P<0.01),应用文拉法辛缓释剂联合森田疗法治疗2mo末,焦虑、抑郁情绪与治疗前比较有显著改善(P<0.01);治疗2、6mo末显效率分别为66.0%和82.0%,差异有极显著性(P<0.01)。结论文拉法辛缓释剂联合森田疗法能很好的改善肠易激综合征患者的情绪状态,缓解躯体症状,疗效显著,安全性高,依从性好。
Objective To explore the effects of venlafaxine retarder plus Morita＇s therapy in irritable bowel syndrome（IBS）. Methods Observational treatment of venlafaxine retarder plus Morita＇s therapy was conducted in 50 patients with the IBS for 6 months, and one course of treatment was 2 months. Clinical effects were assessed with the Self-rating Anxiety Scale（SAS） and the Self-rating Depression Scale（SDS） and compared with national norm. Results Compared with the national norm IBS patients had marked anxious and depressive emotions（P〈0.01）; at the end of 2-month treatment anxious and depressive emotions improved significantly compared with pre-treatment（P〈0.01）; effectual rates were 65.2% and 83. 6% at the ends of 2nd and 6th month respectively, difference was very significant（P〈0.01）. Conclusion The combination of Venlafaxine and Marita therapy could effectively improve the emotional state of the IBS patients and relieve somatizations, and has marked effects ,higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2006年第6期426-427,共2页
Journal of Clinical Psychosomatic Diseases
关键词
肠易激综合征
文拉法辛
森田疗法
Irritable bowel syndrome
venlafaxine
Morita＇s therapy
